Elsevier Inc.

SHERPA: Unknown

People

  1. Lesokhin
    Lesokhin
  2. Hassoun
    Hassoun
  3. Korde
    Korde
  4. Hultcrantz
    Hultcrantz
  5. Landau
    Landau
  6. Mailankody
    Mailankody
  7. Giralt
    Giralt
  8. Shah
    Shah
  9. Chung
    Chung
  10. Usmani
    Usmani

Groups

  1. Center for Hematologic Malignancies (77)
  2. Department of Medicine (77)
  3. Hematologic Malignancies, Division of (77)
  4. Myeloma (77)
  5. Hematologic Malignancies Research (58)
  6. Sloan Kettering Institute Postdocs (39)
  7. Survivorship Research (39)
  8. Bone Marrow Transplant (34)
  9. CTCR Scholars (30)
  10. GME, Medicine (24)
Search Within
  1. "Clinical Lymphoma, Myeloma and Leukemia"
  2. "Myeloma"
Formats
  1. Meeting Abstract (71)
  2. Journal Article (4)
  3. Conference Paper (1)
  4. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (77)
  2. Department of Medicine (77)
  3. Hematologic Malignancies, Division of (77)
  4. Myeloma (77)
  5. Hematologic Malignancies Research (58)
  6. Sloan Kettering Institute Postdocs (39)

More Groups

People
  1. Alexander Lesokhin (44)
  2. Hani Hassoun (40)
  3. Malin Hultcrantz (37)
  4. Neha Korde (34)
  5. Heather Landau (32)
  6. Sham Mailankody (32)

More People

Years
  1. 2023 (27)
  2. 2022 (14)
  3. 2021 (8)
  4. 2020 (5)
  5. 2019 (16)
  6. 2018 (2)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (77)

Results (77)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse national health and nutrition examination survey (NHANES) case-control study
    Meeting Abstract

    Joseph, J.; Tang, L.; Hillengass, J.; Landgren, O.; Usmani, S.; Lesokhin, A.; Moysich, K.; Shah, U.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology
    Meeting Abstract

    Maclachlan, K.; Blaney, P.; Gagler, D.; Boyle, E.; Diamond, B.; Shah, U.; Korde, N.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Individualized risk in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A.; Ziccheddu, B.; Derkach, A.; Poos, A.; Maclachlan, K.; Boyle, E.; Hultcrantz, M.; Silva, A.; Jackson, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Jagannath, S.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: Post-hoc analysis from MagnetisMM-3
    Meeting Abstract

    Leleu, X.; Bahlis, N.; Rodríguez-Otero, P.; Quach, H.; Touzeau, C.; Depaus, J.; Iida, S.; Hänel, M.; Wrobel, T.; Leip, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Cavo, M.; Delforge, M.; Dimopoulos, M.; Escalante, F.; Hultcrantz, M.; Kleinman, D.; Lee, H.; Vij, R.; Kotowsky, N.; Camadoo-O'Byrne, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save